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Objective: The study was designed to evaluate the efﬁ  cacy of an ophthalmic formulation of 
1% azithromycin in DuraSite® (AzaSite™, InSite Vision, Alameda CA, USA) and demonstrate 
equivalence with 0.3% tobramycin ophthalmic solution, USP, for the treatment of bacterial 
conjunctivitis as deﬁ  ned by the resolution of clinical signs and the eradication of pathogens.
Design: Prospective, randomized, active-controlled, double-masked, phase 3 trial conducted 
at 47 US sites between 6 August 2004 and 6 October 2005. Participants: Subjects aged 1 year 
or older with diagnosis of acute bacterial conjunctivitis.
Methods: Bacteriologically conﬁ  rmed participants received either 1% azithromycin in Dura-Site 
(n = 159) or tobramycin (n = 157). Masked study medications were dosed 4 times a day for 
5 days. Participants in the 1% azithromycin in DuraSite group were dosed twice a day with 
active drug on days 1 and 2 and once daily on days 3 through 5. The other doses were vehicle. 
Clinical signs and bacterial cultures were evaluated at visit 3 (day 6 + 1).
Results: Clinical resolution was observed in 79.9% of participants in the 1% azithromycin in 
DuraSite group, as compared with 78.3% of those in the tobramycin group (95% CI: −7.4–10.5). 
Bacterial eradication was 88.1% in the 1% azithromycin in DuraSite group vs 94.3% in the 
tobramycin group (95% CI: −12.4–0.0). Analyses of resistance conﬁ  rmed that 1% azithromycin 
in DuraSite eradicated Staphylococci and Streptococci strains that are commonly resistant to 
azithromycin, erythromycin, and ﬂ  uoroquinolones.
Conclusions: The efﬁ  cacy of 1% azithromycin in DuraSite and tobramycin are equivalent; 
however, this formulation of azithromycin also permits effective dosing intervals of twice a day 
on days 1 and 2 followed by once daily on the last 3 days of therapy, for a total of 65% fewer 
doses. In vitro, the killing spectrum of 1% azithromycin in DuraSite appears to be enhanced 
relative to 1% azithromycin without DuraSite.
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Introduction
Acute bacterial conjunctivitis is an infective condition in which the eyes become red 
and inﬂ  amed. The pathogens vary, but the majority of bacterial conjunctivitis infec-
tions are caused by Haemophilus inﬂ  uenzae, Staphylococcus aureus, or Streptococcus 
pneumoniae (Seal 1982). Common in children, these infections are often self-limiting 
and usually resolve in 8–10 days. Untreated bacterial conjunctivitis in contact lens 
wearers, however, may have very serious consequences because of the potential for 
corneal ulcer development. In addition, epidemics of atypical bacterial conjunctivitis 
have occurred on college campuses (Martin et al 2003), and the threat of contagion 
among children in the US is perceived as sufﬁ  ciently signiﬁ  cant that infected children Clinical Ophthalmology 2007:1(2) 178
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are not allowed to return to school or daycare until they 
have received adequate therapeutic intervention (American 
Academy of Pediatrics 2003).
Effective ocular antibiotics with shorter and more 
simplified dosing regimens could improve treatment 
compliance, thereby improving treatment efﬁ  cacy and reduc-
ing a contagion’s spread (Alvarez-Elcoro and Enzler 1999; 
Kardas 2002). To that end, a new topical ocular solution of 
1% azithromycin was formulated with DuraSite® (AzaSite™, 
InSite Vision, Alameda, CA), an ocular delivery system. 
This delivery vehicle stabilizes azithromycin in an aqueous 
mucoadhesive matrix and permits an increase in the con-
centration of azithromycin in ocular tissue sufﬁ  cient to kill 
bacteria commonly associated with conjunctivitis.
The efﬁ  cacy of 1% azithromycin in DuraSite was com-
pared with that of tobramycin 0.3% eye drops in a therapeutic 
regimen of 5 days. Tobramycin was chosen as the comparator 
owing to its well-known efﬁ  cacy; low side effects proﬁ  le; 
availability in the US; and formulation as an eye drop, which 
allowed for easy masking.
Methods
The primary objective of the study was the clinical resolution 
of the signs and symptoms of infective bacterial conjunctivi-
tis. Resolution was deﬁ  ned as a clinical severity rating of 0 
for each of 3 clinical observations: ocular discharge, bulbar 
injection, and palpebral injection. The secondary objective 
was bacterial eradication, which was deﬁ  ned by the absence 
in culture of the original infecting bacteria. Clinical resolu-
tion and bacterial eradication were both evaluated at the third 
test-of-cure visit (day 6 or 7).
Subjects were deemed eligible if they were 1 year or 
older, with no evidence of debilitating disease. Clinical 
signs necessary for inclusion in the trial included 
purulent conjunctival discharge and conjunctival or 
palpebral injection of no more than 3 days’ duration. 
Individuals were required to exhibit a minimum score of 
grade 1 (0 = absent, 1 = mild, 2 = moderate, 3 = severe) 
for purulent conjunctival discharge and a minimum score 
of grade 1 (0 = normal, 1 = mild, 2 = moderate, 3 = severe) 
for either bulbar or palpebral injection in the same eye. 
Investigators scored the extent of injection by referring 
to standardized photographs (Ophthalmic Research 
Associates, North Andover, MA). At study entry, eligible 
participants had a best corrected visual acuity of 20/100 
or better, and were required to discontinue contact lens 
wear, and, if female, and of child-bearing potential, to test 
negative for pregnancy. Potential participants who had 
used topical ophthalmic solutions or anti-inﬂ  ammatory 
agents prior to study entry were excluded.
Participants were randomized to receive either 1% 
azithromycin in DuraSite or 0.3% tobramycin. Conjunctival 
cultures were obtained from these intent-to-treat participants 
at presentation on day 1. The efﬁ  cacy analysis was performed 
on the per-protocol sample. Those eligible for efﬁ  cacy analysis 
had positive results for bacterial cultures, no major protocol 
violations, and completed at least 1 post-dose follow-up. 
A positive culture was determined by previously deﬁ  ned 
minimum threshold bacterial counts (Cagle et al 1981). 
A sample size of 155 participants per treatment arm was 
deemed sufﬁ  cient for the comparison of equivalence based 
on a power of 0.90, and α = 0.05 (2-sided 95% intervals).
Participants were directed to instill the study medication 
into the worse affected eye 4 times a day. Many patients 
were infected in both eyes (70.6%, 223/316); in these cases 
both eyes were treated. There was no signiﬁ  cant difference 
(p = 0.20) between treatment groups in the proportion of 
participants who received bilateral treatment. If both eyes were 
infected the eye with the worse signs was used for analysis.
The study design is shown in Figure 1.
Results
Randomization
Of the 743 eligible participants who were randomized, 
710 (95.6%) completed the trial. Positive ocular bacterial 
cultures were conﬁ  rmed in 316 (42.5%) participants. Of the 
eligible population, 33 participants were terminated from 
the study before completion. Of these, 17 were dropped as a 
result of adverse events and the remaining 16 were dropped 
because of protocol violations, withdrawn consent, losses 
to follow up, or lack of efﬁ  cacy. The major protocol viola-
tion in this study was failure to return for one of the two 
follow-up visits.
Demographics
The median age of participants in the per-protocol popula-
tion was 20.4 ± 21.5 years (range 1–83). The percent of 
participants 11 years old or younger was 53.8%. The only 
demographic difference between treatment groups that was 
statistically signiﬁ  cant was a difference in mean age of 
approximately 5 years (p = 0.045) (Table 1).
Baseline signs and symptoms
More than 50% of participants were classiﬁ  ed with clinical 
signs and symptoms of moderate severity at the baseline visit 
on day 1. Overall 10% to 13% presented with severe clinical Clinical Ophthalmology 2007:1(2) 179
Comparison of efﬁ  cacy: azithromycin ophthalmic solution, 1%, vs tobramycin
signs (Table 2). There were no signiﬁ  cant differences between 
the treatment groups in the severity of signs and symptoms.
Clinical resolution
The therapy was rated as either a success or failure based 
on the complete resolution of clinical symptoms (Table 3). 
Treatment with 1% azithromycin in DuraSite achieved 
clinical resolution in 79.9% (127/159) of participants; treat-
ment with tobramycin achieved clinical resolution in 78.3% 
(123/157) of participants. The difference in clinical resolu-
tion between the two treatment groups was not statistically 
signiﬁ  cant (p = 0.783).
Investigator ratings of clinical outcomes
Clinical outcomes were based on the investigator severity 
ratings of ocular discharge and injection. At day 3, 93.9% 
of infections that were treated with 1% azithromycin in 
DuraSite were resolved or improved. There were no sta-
tistically signiﬁ  cant differences (p = 0.949) between the 
treatment groups. However, equivalence with tobramycin 
was obtained with 65% fewer drops of 1% azithromycin in 
DuraSite (Table 4).
Bacterial eradication
Cultures of the ocular swabs performed at baseline revealed 
that the distribution and frequency of causative pathogens 
in the two treatment groups was similar. The most prevalent 
bacteria cultured from participants in the 1% azithromycin in 
DuraSite treatment group were H. inﬂ  uenza (42.8%, n = 68), 
S. pneumoniae (39.6%, n = 63), S. aureus (12.6%, n = 20), 
and Staphylococcus epidermis (3.1%, n = 5). The frequencies 
of other pathogens were lower.
Treatment with 1% azithromycin in DuraSite achieved 
bacterial eradication in 88.1% of   participants (140/159). 
Comparably, treatment with tobramycin achieved bacterial erad-
ication in 94.3% (148/157). The difference between treatment 
groups was not statistically signiﬁ  cant (p = 0.073; Table 5).
Supplementary evaluations of eradication with respect 
to gram stain were also performed. At visit 3, eradication of 
gram–positive S. aureus, and S. pneumoniae, was 82.4% and 
87.5%, respectively. The rate of eradication of gram-negative 
H. inﬂ  uenzae was 93%. There were no statistically signiﬁ  cant 
differences between treatment groups in terms of efﬁ  cacy 
against the most common gram-positive and gram-negative 
pathogens of bacterial conjunctivitis.
In vitro sensitivity testing
The resistance patterns in the pathogens isolated from the 
participants were evaluated in vitro using systemic break-
points deﬁ  ned by the Clinical Laboratory and Standards 
Institute (CLSI). Azithromycin in DuraSite effectively 
eradicated several Staphylococci and Streptococci strains 
that were observed to be resistant to azithromycin, erythro-
mycin, levoﬂ  oxacin, gatiﬂ  oxacin, moxiﬂ  oxacin, and oxacillin 
(Table 6).
The azithromycin in DuraSite formulation eradicated 2 of 
4 isolates (50.0%) of azithromycin-resistant S. aureus. Nine of 
15 isolates (60.0%) of resistant gram-negative S. pneumoniae 
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Figure 1 Study design and dosing scheme. Masked study medications were dosed 4 times per day for 5 days. Participants in the azithromycin group only received active 
study medication twice a day on days 1 and 2 and once daily on days 3 through 5. Study visit evaluations included: clinical assessment, best corrected visual acuity, biomicros-
copy, ophthalmoscopy (days 1 and 6 only), and cultures from infected eye(s).Clinical Ophthalmology 2007:1(2) 180
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were also eradicated. Although the incidence was low, 1% 
azithromycin in DuraSite eradicated 100% of the other resis-
tant Staphylococci and Streptococci strains that were cultured 
in this study (Table 6). A similar pattern of eradication was 
observed with tobramycin-resistant pathogens.
A few strains of S. aureus and Staphylococcus simulans 
were resistant to ﬂ  uoroquinolones and oxacillin in culture. 
Azithromycin in DuraSite was able to eradicate half the 
S. aureus and the S. simulans isolates that were resistant 
to the third- and fourth-generation ﬂ  uoroquinolones. The 
azithromycin formulation in DuraSite also eradicated the 
two oxacillin-resistant Staphylococci isolates encountered 
in the study (see Table 6).
By comparison, tobramycin was effective against 83% 
(5/6) of the oxacillin-resistant Staphylococci strains and 
eradicated 76% (19/25) of the azithromycin-resistant bacte-
rial strains tested.
Discussion and conclusions
The efﬁ  cacy of a 5-day regimen of topical 1% azithromycin 
in DuraSite, a new anti-infective eye drop, against infective 
bacterial conjunctivitis was compared with that of 0.3% 
tobramycin ocular solution. Erythromycin, a macrolide, is 
closely related to azithromycin but azithromycin’s pharmaco-
logic proﬁ  le is improved with respect to bacterial eradication 
spectrum, higher tissue penetration, and a longer half-life 
(Neu 1991; Bryskier and Labro 1994).
The formulation of azithromycin in DuraSite forms a 
stable, mucoadhesive matrix that increases the bioavailabil-
ity of azithromycin in the eye. The dosing regimen in this 
clinical trial was twice a day on days 1 and 2 and once daily 
on days 3 through 5.
As with other ocular anti-infectives, the strategy 
employed was to deliver higher drug levels earlier in the 
course of infection when the bacterial burden is likely to 
be highest. The results indicate that the formulation of 1% 
azithromycin in DuraSite was just as effective as tobramycin 
eye drops and demonstrated the potential advantage of requir-
ing 65% fewer drops for a full course of therapy. Likewise 
with respect to bacterial eradication, there was no difference 
in the rate of pathogen clearance over the 5-day course of 
therapy. Coverage of gram-negative and gram-positive 
pathogens was equally effective. The most commonly used 
4th generation ﬂ  uoroquinolone eye drops, moxiﬂ  oxacin and 
Table 1 Study participant demographics in the per-protocol population
1% azithromycin
in DuraSite 
(n = 159)
0.3% tobramycin 
(n = 157)
Total 
(n = 316) p value
Age
Mean ± SD 17.9 ± 20.23 22.8 ± 20.23 20.4 ± 20.23 0.045a
Median (range, y) 8 (1–81) 12 (1–83) 9 (1–83)
Pediatric (1–11 y) 93 (58.5%) 77 (49.0%) 170 (53.8%) 0.114
Non-pediatric (12 y) 66 (49.1%) 80 (42.7%) 146 (45.9%)
Non-geriatric (65 y) 153 (96.2%) 147 (93.6%) 300 (94.9%) 0.317
Geriatric (65 y) 6 (3.8%) 10 (6.4%) 16 (5.1%)
Sex
Male 78 (49.1%) 67 (47.2%) 145 (45.9%) 0.261
Female 81 (50.9%) 90 (57.3%) 171 (54.1%)
Race
White 113 (71.1%) 100 (63.7%) 213 (67.4%) 0.429
Black 10 (6.3%) 15 (9.6%) 25 (7.9%)
Asian or Paciﬁ  c Islander 3 (1.9%) 4 (2.5%) 7 (2.2%)
Hispanic 29 (18.2%) 37 (23.6%) 66 (20.9%)
Native American or Alaskan 1 (0.6%) 0 1 (0.3%)
Other 3 (1.9%) 1 (0.6%) 4 (1.3%)
Eye color
Brown 82 (51.6%) 78 (49.7%) 160 (50.6%) 0.202
Blue 50 (31.4%) 48 (30.6%) 98 (31.0%)
Green 12 (7.5%) 5 (3.2%) 17 (5.4%)
Hazel 12 (7.5%) 21 (13.4%) 33 (10.4%)
Other 3 (1.9%) 5 (3.2%) 8 (2.5%)
Iris color (hue)
Dark 84 (52.8%) 83 (52.9%) 167 (52.8%) 0.191
Hazel 12 (7.5%) 21 (13.4%) 33 (10.4%)
Light 63 (39.6%) 53 (33.8%) 116 (36.7%)
ap  0.05; p value from Fisher Exact Test.Clinical Ophthalmology 2007:1(2) 181
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gatiﬂ  oxacin, are indicated to be dosed 3–8 times per day, 
respectively, for the ﬁ  rst 2 days of therapy. From days 3–7, 
moxiﬂ  oxacin is continued to be dosed 3 times per day and 
gatiﬂ  oxacin is tapered to 4 times per day. The 1% azithro-
mycin in DuraSite formulation supports a simpliﬁ  ed dosing 
regimen that is tapered from twice a day to once daily. This 
is of clinical value for any patient.
It was of particular interest to learn whether 1% 
azithromycin in DuraSite can eradicate pathogens that 
are considered resistant to azithromycin as determined by 
CLSI systemic breakpoints. One problem with using these 
breakpoints to assess resistance is that they have never been 
evaluated in ocular tissue. In this study, 1% azithromycin in 
DuraSite eradicated pathogens that in vitro were resistant 
to azithromycin, erythromycin, and fluoroquinolones, 
suggesting that the systemic breakpoints may not be broadly 
applicable to ocular surface infections.
In addition to the majority of resistant S. aureus isolates, 
1% azithromycin in DuraSite eradicated a strain of coagu-
lase-negative S. simulans that was resistant to azithromycin, 
the ﬂ  uoroquinolones, and oxacillin. Many reports show 
that oxacilin- and methicillin-resistant S. aureus are emerg-
ing causes of nosocomial and community-associated 
infections. Two oxacillin-resistant isolates were encoun-
tered and successfully eradicated in this study population. 
Others have reported that currently available formulations 
of oral azithromycin result in suboptimal efﬁ  cacy against 
S. pneumoniae (Jacobs 2004; Hyde et al 2001). In this study, 
1% azithromycin in DuraSite eradicated 60% of resistant 
S. pneumoniae from the ocular surface. Although the total 
number of resistant isolates in this study was small, these 
data indicate that the ocular preparation of 1% azithromycin 
in DuraSite has a broader killing spectrum than that usually 
attributed to azithromycin without DuraSite. These results 
require further study.
One other important consideration is that because the 
1% azithromycin in DuraSite formulation is a gel-forming 
drop, it persists on the ocular surface longer than conven-
tional aqueous eye drops. This enhances the bioavailability 
Table 2 Clinical signs and symptoms at baseline
1% 
azithromycin 
in DuraSite 
(n = 159)
0.3% 
tobramycin
(n = 157)
Total 
(n = 316)
Ocular discharge
Absent 0 0 0
Mild 54 (34.0%) 61 (38.9%) 115 (36.4%)
Moderate 83 (52.2%) 82 (52.2%) 165 (52.2%)
Severe 22 (13.8%) 14 (8.9%) 36 (11.4%)
Bulbar conjunctival
injection
Normal 1 (0.6%) 1 (0.6%) 2 (0.6%)
Mild 54 (34.0%) 43 (27.4%) 97 (30.7%)
Moderate 89 (56.0%) 95 (60.5%) 184 (58.2%)
Severe 15 (9.4) 18 (11.5%) 33 (10.4%)
Palpebral conjunctival
injection
Normal 3 (1.9%) 2 (1.3%) 5 (1.6%)
Mild 53 (33.3%) 54 (34.4%) 107 (33.9%)
Moderate 85 (53.5%) 78 (49.7%) 163 (51.6%)
Severe 18 (11.3%) 23 (14.6%) 41 (13.0%)
Table 3 Clinical resolution
1% azithromycin 
in DuraSite 
(n = 159)
0.3%
tobramycin 
(n = 157)
Difference 
(CI) p valuea
Visit 3
Success 127 (79.9%) 123 (78.3%) 1.5 0.783
Failure 32 (20.1%) 34 (121.7%) (−7, 4, 10.5)
ap value from Fisher Exact Test. Difference (azithromycin-tobramycin) and conﬁ  -
dence interval (CI) for the difference in success rate is based on normal approxi-
mation for large samples without stratiﬁ  cation by center.
Table 4 Clinical outcome
Global rating 1% 
azithromycin 
in DuraSite
0.3% 
tobramycin p valuea
Visit 2 (day 3–4) (n = 148) (n = 148)
Resolution 37 (25.0%) 38 (25.7%) 0.488
Improved 102 (68.9%) 107 (72.3%)
No Change 7 (4.7%) 3 (2.0%)
Worse 2 (1.4%) 0
Visit 3 (day 6 + 1) (n = 159) (n = 157)
Resolution 127 (79.9%) 123 (78.3%) 0.743
Improved 30 (18.9%) 32 (20.4%)
No change 0 1 (0.6%)
Worse 2 (1.3%) 1 (0.6%)
ap values from Fisher Exact Test.
Table 5 Bacterial eradicationa
1% azithromycin 
in DuraSite 
(n = 159)
0.3% 
tobramycin 
(n = 157)
Difference
(CI) p valueb
Visit 3
Success 140 (88.1%) 148 (94.3%) −6.2 0.073
Failure 19 (1 1.9%) 9 (5.7%) (−12.4, 0.0)
aEradication was demonstrated as the absence in culture at visit 3 (day 6 + 1) of 
suprathreshold levels of pathogens that were found at baseline (visit 1, day 1).
bp value from Fisher Exact Test.Clinical Ophthalmology 2007:1(2) 182
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of azithromycin in the conjunctiva and potentially maximizes 
concentration-dependent azalide activity on the ocular 
surface.
There is a medical need for topical antibiotic choices 
in ophthalmology. Treatment failures may occur when 
patients dose at the wrong intervals, skip doses, or do not 
complete the full course of therapy. This in turn decreases 
the effectiveness of the immediate treatment and increases 
the likelihood that bacteria will develop resistance and will 
not be treatable by antibacterial drugs in the future. Patient 
and caregiver education is needed to make sure that antibiot-
ics are taken as prescribed. The results of this clinical trial 
show that 1% azithromycin in DuraSite provides effective 
antibiotic coverage against the most common bacteria seen 
in bacterial conjunctivitis with a topical dosing regimen of 
just 7 drops.
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